Overview

TB Host Directed Therapy

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.
Phase:
Phase 2
Details
Lead Sponsor:
The Aurum Institute NPC
Treatments:
Auranofin
Cholecalciferol
Ergocalciferols
Everolimus
Rifabutin
Sirolimus
Vitamin D
Vitamins